PARIS, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Deinove (Alternext Paris:ALDEI), a cleantech company that designs, develops and markets the next generation of industrial processes based on deinococcus bacteria, has announced that the award of its major patent EP2209900 was published in issue 13/23 of the European Patent Bulletin on 5 June 2013.
The invention involves the pioneering use of deinococcus bacteria to produce biofuels (biodiesel and bioalcohol such as ethanol, butanol, butanediol and cellulosic biofuels) and metabolites of industrial interest (e.g. organic acids).
The bacteria, which have rare genetic and metabolic properties, are able to manufacture these molecules from plant biomass components that other living organisms are virtually unable to use. They can convert a large number of raw materials (straw, wood, forestry and agricultural residues, organic, household or industrial waste) into valuable products, utilizing their main constituents (cellulose, hemicellulose, xylan, xylose, arabinoxylan, starch, glucose, etc.).
The patent has been co-signed by Jean-Paul Leonetti, DEINOVE's R&D Director and CNRS senior researcher, Jacques Biton, Ivan Matic, from the Scientific Advisory Board and Philippe Pouletty, the Chairman and cofounder of the company.
"We are delighted with the award of this broad patent, which marks an essential stage in our roadmap," said Emmanuel Petiot, DEINOVE's Chief Executive Officer. He added, "The invention paves the way for high-performance production systems that are of high performance, economically viable and ecologically much more efficient. It puts DEINOVE in pole position for an ambitious penetration of the global market in second-generation biofuels and green chemistry with the help of these exceptional bacteria."
For more information on patent EP2209900: https://register.epo.org/application?number=EP08848694
DEINOVE (Alternext Paris:ALDEI) is a cleantech company that designs and develops new production standards based on bacteria with still untapped potential: deinococcus.
Building on their unique genetic properties and extraordinary resilience, DEINOVE optimizes the natural metabolic and fermentation capabilities of these bacterial "micro-factories" to manufacture products that are rare or technologically difficult to produce: second-generation biofuels (DEINOL), chemical intermediates (DEINOCHEM), new antibiotics (through the specialist affiliate DEINOBIOTICS SAS) and enzymes for plastic remediation (THANAPLAST(TM) collaborative project led by CARBIOS).
DEINOVE, which has been Alternext listed since April 2010, was founded by Dr Philippe Pouletty, Chief Executive Officer of TRUFFLE CAPITAL, and Prof. Miroslav Radman from René Descartes University's Faculty of Medicine. It has a workforce of thirty and conducts its R&D programmes in partnership with the CNRS (Marseille and Montpellier), INSA (Toulouse) and VTT (Finland). DEINOVE's head office and laboratories are located in Paris and at Technoparc Cap Alpha in Montpellier respectively.
More information at www.deinove.com
Deinove European Patent: http://hugin.info/142979/R/1728108/577049.pdf
CONTACT: DEINOVE Emmanuel Petiot Chief Executive Officer Tel: + 33 142 032737 email@example.com ATCG Press Marielle Bricman Press relations Mob: +33 626 941853 firstname.lastname@example.org Elisabetta Castelli Director of Communications and Investor Relations Mob: +33 613 663939 email@example.com